{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:32:30Z","timestamp":1792114350378,"version":"4.4.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"am","delay-in-days":362,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["XDB39000000"],"award-info":[{"award-number":["XDB39000000"]}],"id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82030034"],"award-info":[{"award-number":["82030034"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32121002"],"award-info":[{"award-number":["32121002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003345","name":"Chinese Academy of Meteorological Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003345","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["YD9110002033"],"award-info":[{"award-number":["YD9110002033"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["YD9110002027"],"award-info":[{"award-number":["YD9110002027"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Science Bulletin"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.scib.2024.09.042","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T19:35:38Z","timestamp":1727552138000},"page":"3777-3784","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Now and future: Strategies for diagnosis, prevention and therapies for Alzheimer\u2019s disease"],"prefix":"10.1016","volume":"69","author":[{"given":"Jiong","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Touchon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lefkos T","family":"Middleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e9 Boada","family":"Rovira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Vassar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Vellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.scib.2024.09.042_b0005","doi-asserted-by":"crossref","first-page":"532","DOI":"10.14283\/jpad.2022.46","article-title":"Clinical research investigating Alzheimer's disease in China: current status and future perspectives toward prevention","volume":"9","author":"Wang","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.scib.2024.09.042_b0010","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/alz.12362","article-title":"Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020\u20132060)","volume":"17","author":"Rajan","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.scib.2024.09.042_b0015","doi-asserted-by":"crossref","first-page":"e661","DOI":"10.1016\/S2468-2667(20)30185-7","article-title":"Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: A cross-sectional study","volume":"5","author":"Jia","year":"2020","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.scib.2024.09.042_b0020","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1002\/alz.12655","article-title":"Evaluation of major national dementia policies and health-care system preparedness for early medical action and implementation","volume":"18","author":"Hampel","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.scib.2024.09.042_b0025","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/alz.12328","volume":"17","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.scib.2024.09.042_b0030","unstructured":"Alzheimer Europe (2019). Dementia in Europe Yearbook 2019 - Estimating the prevalence of dementia in Europe 2019. https:\/\/www.alzheimer-europe.org\/sites\/default\/files\/alzheimer_europe_dementia_in_europe_yearbook_2019.pdf\uff08Accessed Sep 20, 2024\uff09"},{"key":"10.1016\/j.scib.2024.09.042_b0035","article-title":"Global mortality from dementia: Application of a new method and results from the Global Burden of Disease Study 2019","volume":"7","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.scib.2024.09.042_b0040","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3233\/JAD-210075","article-title":"Economic burden of Alzheimer's disease dementia in Japan","volume":"81","author":"Ikeda","year":"2021","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.scib.2024.09.042_b0045","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1474-4422(19)30290-X","article-title":"Dementia in China: epidemiology, clinical management, and research advances","volume":"19","author":"Jia","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.scib.2024.09.042_b0050","doi-asserted-by":"crossref","first-page":"20235","DOI":"10.1038\/s41598-019-56388-w","article-title":"Place of death trends among patients with dementia in Japan: A population-based observational study","volume":"9","author":"Koyama","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.scib.2024.09.042_b0055","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1186\/s12877-021-02540-z","article-title":"Future projections of the prevalence of dementia in Japan: Results from the Toyama dementia survey","volume":"21","author":"Nakahori","year":"2021","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.scib.2024.09.042_b0060","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h3029","article-title":"Dementia: Timely diagnosis and early intervention","volume":"350","author":"Robinson","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.scib.2024.09.042_b0065","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.scib.2024.09.042_b0070","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","article-title":"Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria","volume":"6","author":"Dubois","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.scib.2024.09.042_b0075","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jalz.2011.03.004","article-title":"Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Jack","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.scib.2024.09.042_b0080","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: Toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.scib.2024.09.042_b0085","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jalz.2018.03.005","article-title":"Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical disease","volume":"14","author":"Brookmeyer","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.scib.2024.09.042_b0090","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jamaneurol.2019.1424","article-title":"Association of amyloid and Tau with cognition in preclinical Alzheimer disease: A longitudinal study","volume":"76","author":"Hanseeuw","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.scib.2024.09.042_b0095","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","article-title":"Clinical diagnosis of Alzheimer's disease: Recommendations of the International working group","volume":"20","author":"Dubois","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.scib.2024.09.042_b0100","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","article-title":"Blood-based biomarkers for Alzheimer's disease: Towards clinical implementation","volume":"21","author":"Teunissen","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.scib.2024.09.042_b0105","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000111693","article-title":"Cognitive decline and survival in Alzheimer's disease according to education level","volume":"25","author":"Bruandet","year":"2008","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.scib.2024.09.042_b0110","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1186\/s12883-021-02487-z","article-title":"Anaemia and cerebrospinal fluid biomarkers of Alzheimer's pathology in cognitively normal elders: The CABLE study","volume":"21","author":"Yang","year":"2021","journal-title":"BMC Neurol"},{"key":"10.1016\/j.scib.2024.09.042_b0115","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.749649","article-title":"Performance of plasma amyloid beta, total Tau, and neurofilament light chain in the identification of probable Alzheimer's disease in South China","volume":"13","author":"Jiao","year":"2021","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.scib.2024.09.042_b0120","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/alz.12700","article-title":"A combination model of AD biomarkers revealed by machine learning precisely predicts Alzheimer's dementia: China aging and neurodegenerative initiative (CANDI) study","volume":"19","author":"Gao","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"68","key":"10.1016\/j.scib.2024.09.042_b0125","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/j.scib.2023.07.009","article-title":"China Aging and Neurodegenerative Initiative (CANDI) Consortium. blood-based biomarkers for Alzheimer's disease: A multicenter-based cross-sectional and longitudinal study in China","volume":"30","author":"Gao","year":"2023","journal-title":"Sci Bull"},{"key":"10.1016\/j.scib.2024.09.042_b0130","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/clinchem\/hvab192","article-title":"Development of a plasma biomarker diagnostic model incorporating ultrasensitive digital immunoassay as a screening strategy for Alzheimer disease in a Chinese population","volume":"67","author":"Wu","year":"2021","journal-title":"Clin Chem"},{"key":"10.1016\/j.scib.2024.09.042_b0135","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13195-021-00864-x","article-title":"Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum of Alzheimer's disease","volume":"13","author":"Xiao","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.scib.2024.09.042_b0140","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.biopsych.2017.02.007","article-title":"Increased plasma beta-secretase 1 may predict conversion to Alzheimer's disease dementia in individuals with mild cognitive impairment","volume":"83","author":"Shen","year":"2018","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.scib.2024.09.042_b0145","article-title":"Association of naturally occurring antibodies to beta-amyloid with cognitive decline and cerebral amyloidosis in Alzheimer's disease","volume":"7","author":"Liu","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.scib.2024.09.042_b0150","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/alz.12369","article-title":"Large-scale plasma proteomic profiling identifies a high-performance biomarker panel for Alzheimer's disease screening and staging","volume":"18","author":"Jiang","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.scib.2024.09.042_b0155","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13195-022-00988-8","article-title":"Automatized FACEmemory\u00ae scoring is related to Alzheimer\u2019s disease phenotype and biomarkers in early-onset mild cognitive impairment: The BIOFACE cohort","volume":"14","author":"Alegret","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.scib.2024.09.042_b0160","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006189","article-title":"Neuropathological alterations in Alzheimer disease","volume":"1","author":"Serrano-Pozo","year":"2011","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.scib.2024.09.042_b0165","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.jalz.2019.05.002","article-title":"Concordance between the assessment of A\u03b242, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid","volume":"15","author":"Jia","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.scib.2024.09.042_b0170","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","article-title":"The amyloid hypothesis in Alzheimer disease: New insights from new therapeutics","volume":"21","author":"Karran","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.scib.2024.09.042_b0175","article-title":"Alzheimer's disease beyond amyloid: strategies for future therapeutic interventions","volume":"371","author":"Shi","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.scib.2024.09.042_b0180","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of Solanezumab for mild dementia due to Alzheimer's disease","volume":"378","author":"Honig","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.scib.2024.09.042_b0185","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13195-022-01110-8","article-title":"Gantenerumab: An anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease","volume":"14","author":"Bateman","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.scib.2024.09.042_b0190","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/alz.12286","article-title":"ENGAGE and EMERGE: Truth and consequences?","volume":"17","author":"Kuller","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.scib.2024.09.042_b0195","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.scib.2024.09.042_b0200","unstructured":"Company ELa. Lilly's Donanemab significantly slowed cognitive and functional decline in phase 3 study of early Alzheimer's disease. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-donanemab-significantly-slowed-cognitive-and-functional."},{"key":"10.1016\/j.scib.2024.09.042_b0205","unstructured":"Shanghai Hengrui Pharmaceutical Co. Ltd. A Phase Ib, Randomized, double-blind, placebo-controlled, multiple-ascending dose study to evaluate the safety, tolerability and pharmacodynamics of intravenous administration of SHR-1707 in patients with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease. https:\/\/clinicaltrials.gov\/study\/NCT05681819."},{"key":"10.1016\/j.scib.2024.09.042_b0210","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: Appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.scib.2024.09.042_bib347","unstructured":"Park B. Aducanumab Significantly Reduces Tau Pathology, Clinical Decline in Alzheimer Disease [online]. https:\/\/www.empr.com\/home\/news\/aducanumab-significantly-reduces-tau-pathology-clinical-decline-in-alzheimer-disease\/(Accessed Sep 20, 2024)."},{"key":"10.1016\/j.scib.2024.09.042_b0220","unstructured":"Eli Lilly and Co. Status of Eli Lilly\u2019s new Alzheimer\u2019s drug: Donanemab. https:\/\/www.dementiacarecentral.com\/aboutdementia\/treating\/donanemab."},{"key":"10.1016\/j.scib.2024.09.042_b0225","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1001\/jamaneurol.2022.2793","article-title":"Association of amyloid reduction after Donanemab treatment with Tau pathology and clinical outcomes: The TRAILBLAZER-ALZ randomized clinical trial","volume":"79","author":"Shcherbinin","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.scib.2024.09.042_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.medp.2024.100005","article-title":"Targeting protein aggregation for the treatment of neurodegenerative diseases","volume":"1","author":"Li","year":"2024","journal-title":"Med Plus"},{"key":"10.1016\/j.scib.2024.09.042_b0235","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41591-021-01455-x","article-title":"Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: A phase 2, randomized, placebo-controlled trial","volume":"27","author":"Dam","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.scib.2024.09.042_b0240","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S1474-4422(20)30489-0","article-title":"Safety and efficacy of tilavonemab in progressive supranuclear palsy: A phase 2, randomised, placebo-controlled trial","volume":"20","author":"Hoglinger","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.scib.2024.09.042_b0245","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/brain\/awad024","article-title":"Tilavonemab in early Alzheimer's disease: Results from a phase 2, randomized, double-blind study","volume":"146","author":"Florian","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.scib.2024.09.042_b0250","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/jamaneurol.2019.3812","article-title":"Reactions to multiple ascending doses of the microtubule stabilizer TPI-287 in patients with Alzheimer disease, progressive supranuclear palsy, and corticobasal syndrome: A randomized clinical trial","volume":"77","author":"Tsai","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.scib.2024.09.042_b0255","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/14728222.2021.1939681","article-title":"The emerging role of the sigma-1 receptor in autophagy: Hand-in-hand targets for the treatment of Alzheimer's","volume":"25","author":"Prasanth","year":"2021","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.scib.2024.09.042_b0260","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/npp.2013.70","article-title":"Blockade of Tau hyperphosphorylation and A\u03b21-42 generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and \u03c31 receptor agonist, in a nontransgenic mouse model of Alzheimer's disease","volume":"38","author":"Lahmy","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.scib.2024.09.042_b0265","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/s41591-023-02326-3","article-title":"Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: A phase 1b, randomized, placebo-controlled trial","volume":"29","author":"Mummery","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.scib.2024.09.042_b0270","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1038\/s41591-022-01926-9","article-title":"Anti-inflammatory clearance of amyloid-beta by a chimeric Gas6 fusion protein","volume":"28","author":"Jung","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.scib.2024.09.042_b0275","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jamaneurol.2022.3392","article-title":"Association of Donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: A secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial","volume":"79","author":"Pontecorvo","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.scib.2024.09.042_b0280","unstructured":"Novartis Pharmaceuticals. Exploratory pLatform trial on anti-inflammatory agents in Alzheimer's disease (EXPLAIN-AD): A randomized, placebo-controlled, multicenter platform study to evaluate the efficacy, safety, tolerability and pharmacokinetics of various anti-inflammatory agents in patients with mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's disease. \u200bhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT04795466\uff08Accessed Sep 20, 2024\uff09"},{"key":"10.1016\/j.scib.2024.09.042_b0285","volume":"20","year":"2024","journal-title":"Inmune Bio I, Inc. Phase 1b open-label, dose-identification study of XPro1595 in patients with Alzheimer\u2019s disease and biomarkers of inflammation"},{"key":"10.1016\/j.scib.2024.09.042_b0290","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1021\/acsptsci.0c00073","article-title":"Compound AD16 reduces amyloid plaque deposition and modifies microglia in a transgenic mouse model of Alzheimer's disease","volume":"3","author":"Sun","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.scib.2024.09.042_b0295","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.cell.2009.12.044","article-title":"Forgetting is regulated through Rac activity in Drosophila","volume":"140","author":"Shuai","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.scib.2024.09.042_b0300","unstructured":"Beijing Joekai Biotechnology LLC. A phase IIa, double-blind, randomized, placebo-controlled, multicenter study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of 50561 in patients with mild or moderate Alzheimer's disease. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05811442."},{"key":"10.1016\/j.scib.2024.09.042_b0305","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41422-019-0216-x","article-title":"Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression","volume":"29","author":"Wang","year":"2019","journal-title":"Cell Res"},{"key":"10.1016\/j.scib.2024.09.042_b0310","unstructured":"Green Valley (Shanghai) Pharmaceuticals Co. Ltd. A clinical study to evaluate the long-term efficacy and safety of sodium oligomannate capsules (GV-971) Sep;20:2024. https:\/\/clinicaltrials.gov\/study\/NCT05181475 (Accessed Sep 20, 2024)."},{"key":"10.1016\/j.scib.2024.09.042_b0315","volume":"20","author":"Green Valley (Shanghai) Pharmaceuticals","year":"2024","journal-title":"A clinical study to evaluate the long-term safety sodium oligomannate capsules (GV-971)"},{"key":"10.1016\/j.scib.2024.09.042_b0320","volume":"20","author":"Green Valley (Shanghai) Pharmaceuticals","year":"2024","journal-title":"An efficacy and safety study of sodium oligomannate (GV-971) for the treatment of Alzheimer\u2019s disease. 2023"},{"key":"10.1016\/j.scib.2024.09.042_b0325","unstructured":"World Health Organization. Dementia. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia."},{"key":"10.1016\/j.scib.2024.09.042_b0330","unstructured":"Alzheimer's Impact Movement. Alzheimer's and related dementia research funding at the NIH. https:\/\/www.alzimpact.org\/appropriations(Accessed Sep 20, 2024)."},{"key":"10.1016\/j.scib.2024.09.042_b0335","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1016\/j.scib.2022.12.006","article-title":"Alzheimer\u2019s disease: current status and perspective","volume":"67","author":"Liu","year":"2022","journal-title":"Sci Bull"},{"key":"10.1016\/j.scib.2024.09.042_b0340","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.scib.2023.02.023","article-title":"China brain project: from bench to bedside","volume":"68","author":"Liu","year":"2023","journal-title":"Sci Bull"},{"key":"10.1016\/j.scib.2024.09.042_b0345","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.scib.2023.07.006","article-title":"Drugging \u201cundruggable\u201d neurodegenerative disease targets with small molecules","volume":"68","author":"Lu","year":"2023","journal-title":"Sci Bull"}],"container-title":["Science Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095927324007151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095927324007151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:09:29Z","timestamp":1762600169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2095927324007151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":69,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2095927324007151"],"URL":"https:\/\/doi.org\/10.1016\/j.scib.2024.09.042","relation":{},"ISSN":["2095-9273"],"issn-type":[{"value":"2095-9273","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Now and future: Strategies for diagnosis, prevention and therapies for Alzheimer\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Science Bulletin","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.scib.2024.09.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Science China Press. Published by Elsevier B.V. and Science China Press. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}